DE69130292T2 - Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on - Google Patents

Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on

Info

Publication number
DE69130292T2
DE69130292T2 DE69130292T DE69130292T DE69130292T2 DE 69130292 T2 DE69130292 T2 DE 69130292T2 DE 69130292 T DE69130292 T DE 69130292T DE 69130292 T DE69130292 T DE 69130292T DE 69130292 T2 DE69130292 T2 DE 69130292T2
Authority
DE
Germany
Prior art keywords
phenyl
benzisoselenazole
benzisoselenazol
ebselen
cisplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69130292T
Other languages
English (en)
Other versions
DE69130292D1 (de
Inventor
Glenn Baldew
N Vermeulen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Rhone Poulenc Rorer GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer GmbH filed Critical Rhone Poulenc Rorer GmbH
Priority to DE69130292T priority Critical patent/DE69130292T2/de
Application granted granted Critical
Publication of DE69130292D1 publication Critical patent/DE69130292D1/de
Publication of DE69130292T2 publication Critical patent/DE69130292T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69130292T 1990-08-06 1991-07-31 Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on Expired - Lifetime DE69130292T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE69130292T DE69130292T2 (de) 1990-08-06 1991-07-31 Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4024885A DE4024885C2 (de) 1990-08-06 1990-08-06 Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
PCT/EP1991/001438 WO1992002221A1 (en) 1990-08-06 1991-07-31 Use of 2-phenyl-1,2-benzisoselenazol-3(2h)-one
DE69130292T DE69130292T2 (de) 1990-08-06 1991-07-31 Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on

Publications (2)

Publication Number Publication Date
DE69130292D1 DE69130292D1 (de) 1998-11-05
DE69130292T2 true DE69130292T2 (de) 1999-04-08

Family

ID=6411708

Family Applications (2)

Application Number Title Priority Date Filing Date
DE4024885A Expired - Lifetime DE4024885C2 (de) 1990-08-06 1990-08-06 Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
DE69130292T Expired - Lifetime DE69130292T2 (de) 1990-08-06 1991-07-31 Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE4024885A Expired - Lifetime DE4024885C2 (de) 1990-08-06 1990-08-06 Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on

Country Status (8)

Country Link
EP (1) EP0542807B1 (de)
JP (1) JP3084062B2 (de)
AT (1) ATE171621T1 (de)
CA (1) CA2088760C (de)
DE (2) DE4024885C2 (de)
DK (1) DK0542807T3 (de)
ES (1) ES2123510T3 (de)
WO (1) WO1992002221A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2553434B2 (ja) * 1992-04-28 1996-11-13 第一製薬株式会社 粒状製剤
US6335036B1 (en) 1993-10-27 2002-01-01 Daiichi Pharmaceutical Co., Ltd. Granular pharmaceutical preparation of ebselen
EP0826370B1 (de) * 1996-08-27 2002-06-19 A. Nattermann & Cie. GmbH Pharmazeutische Zubereitung, die 2-Phenyl-1,2-Benzoisoelenazol-3(2H)-one enthält, für die Behandlung der Alzheimer-Krankheit
DE19825746A1 (de) * 1998-06-09 1999-12-16 Biosyn Arzneimittel Gmbh Kombination von Selen-haltigen Verbindungen mit Zytostatika
CN1166651C (zh) * 2001-06-08 2004-09-15 北京大学药学院 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物
JP2005510471A (ja) * 2001-09-24 2005-04-21 トスク インコーポレーティッド 減少した毒性のシスプラチン製剤及びそれを使用する方法
US20030157191A1 (en) 2001-11-29 2003-08-21 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
ES2497716T3 (es) 2002-01-04 2014-09-23 Sound Pharmaceuticals Incorporated Composiciones para utilizar en métodos destinados a tratar la pérdida auditiva
CA2600134A1 (en) * 2005-03-08 2006-09-14 Sound Pharmaceuticals Incorporated Methods and compositions for treating cancer
GB201102248D0 (en) 2011-02-09 2011-03-23 Isis Innovation Treatment of bipolar disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3027073C2 (de) * 1980-07-17 1985-03-07 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Präparate, enthaltend 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
DE3616923A1 (de) * 1986-05-20 1987-11-26 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
DE3638124C2 (de) * 1986-11-08 1996-09-05 Nattermann A & Cie Neue pharmazeutische Verwendung von Ebselen
DE3821392A1 (de) * 1988-06-24 1989-12-28 Nattermann A & Cie Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on (ebselen)

Also Published As

Publication number Publication date
DE4024885C2 (de) 2002-07-18
CA2088760C (en) 2002-05-07
DE4024885A1 (de) 1992-02-13
ES2123510T3 (es) 1999-01-16
EP0542807A1 (de) 1993-05-26
ATE171621T1 (de) 1998-10-15
WO1992002221A1 (en) 1992-02-20
CA2088760A1 (en) 1993-02-01
JP3084062B2 (ja) 2000-09-04
DK0542807T3 (da) 1999-06-21
EP0542807B1 (de) 1998-09-30
DE69130292D1 (de) 1998-11-05
JPH05509309A (ja) 1993-12-22

Similar Documents

Publication Publication Date Title
ATE32730T1 (de) Indikatormarkierte konjugate von metallothionein und zielsuchenden, biologisch aktiven molekuelen.
FI932032A0 (fi) Kinazolinderivat foer oekande av antitumoeraktivitet
ATE45942T1 (de) Diarylacetylene, ihre herstellung und verwendung.
DE69130292D1 (de) Verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on
SE9101815L (sv) Behandling av sjukdom foerbunden med hiv-infektioner
DE3686582D1 (de) Behandlung einer krankheit vom aids-typ.
HK107596A (en) 5-Amino or substituted amino 1,2,3-triazoles useful as antiproliferative agents
DE3770184D1 (de) Behandlung von gasstroemen.
ES465173A1 (es) Un procedimiento para la preparacion de nuevas benzoisotia- zolonas.
DE3888994D1 (de) Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
DK278788A (da) Ostomikobling
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
NO894281D0 (no) Stabile parenterale opploesninger av 2-fenyl-1,2-benzisoselenazol-3(h)-on og fremgangsmaate for fremstilling av samme.
NO993360L (no) Anvendelse av pramipeksol ved behandling av "restless leg"- syndromet
ATE167804T1 (de) Verwendung von nickel und bromide ionen für die behandlung von psoriasis
DE3576689D1 (de) Oxa- und thiadiazolylderivate und ihre verwendung.
ES2080855T3 (es) Pirido-oxacinas sustituidas.
DE69015344T2 (de) Phosphatzusammensetzungen, gesinterter Körper davon und Herstellung dieses gesinterten Körpers.
DE68900867D1 (de) 1,5-benzothiazepinderivate, ihre herstellung und ihre verwendung in der behandlung von kardiovasculaeren stoerungen.
TR199801902A2 (xx) S�lfonamid ile s�bstit�e edilmi� kromanlar, bunlar� i�eren farmakolojik bile�imler.
ATE67992T1 (de) In 4-stellung durch stickstoff substituierte isochinolinolverbindungen mit cardiotonischen, die wirkung von phosphodiesterase-fraktion-iii inhibierenden und/oder renal vasodilatierenden eigenschaften.
EP0270841A3 (de) 2-Methyl-3-(p-methyl-phenyl)-propionitril, dessen Herstellung und Verwendung als Riechstoff
ATE5144T1 (de) Thiazolderivate, ihre herstellung und ihre therapeutische anwendung.
ATE303158T1 (de) Verwendung von beta-interferon zur behandlung der restenose
TR200003084T2 (tr) Paroxetine askorbat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition